Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
34 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Chroma Therapeutics Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Chroma Therapeutics Ltd. - Product Pipeline Review - 2014', provides an overview of the Chroma Therapeutics Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Chroma Therapeutics Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Chroma Therapeutics Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Chroma Therapeutics Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Chroma Therapeutics Ltd.'s pipeline products Reasons to buy - Evaluate Chroma Therapeutics Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Chroma Therapeutics Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Chroma Therapeutics Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Chroma Therapeutics Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Chroma Therapeutics Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Chroma Therapeutics Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Chroma Therapeutics Ltd. Snapshot 5 Chroma Therapeutics Ltd. Overview 5 Key Information 5 Key Facts 5 Chroma Therapeutics Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 Chroma Therapeutics Ltd. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Chroma Therapeutics Ltd. - Pipeline Products Glance 13 Chroma Therapeutics Ltd. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Chroma Therapeutics Ltd. - Early Stage Pipeline Products 15 Discovery Products/Combination Treatment Modalities 15 Chroma Therapeutics Ltd. - Drug Profiles 16 tosedostat 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CHR-3996 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 tefinostat 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CHR-5250 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CHR-5623 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 CHR-6576 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecules for Inflammation 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecules to Antagonize CSF-1 Receptor for Oncology 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Chroma Therapeutics Ltd. - Pipeline Analysis 25 Chroma Therapeutics Ltd. - Pipeline Products by Target 25 Chroma Therapeutics Ltd. - Pipeline Products by Route of Administration 26 Chroma Therapeutics Ltd. - Pipeline Products by Molecule Type 27 Chroma Therapeutics Ltd. - Pipeline Products by Mechanism of Action 28 Chroma Therapeutics Ltd. - Recent Pipeline Updates 29 Chroma Therapeutics Ltd. - Dormant Projects 31 Chroma Therapeutics Ltd. - Locations And Subsidiaries 32 Head Office 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 34 Disclaimer 34
List of Tables Chroma Therapeutics Ltd., Key Information 5 Chroma Therapeutics Ltd., Key Facts 5 Chroma Therapeutics Ltd. - Pipeline by Indication, 2014 8 Chroma Therapeutics Ltd. - Pipeline by Stage of Development, 2014 9 Chroma Therapeutics Ltd. - Monotherapy Products in Pipeline, 2014 10 Chroma Therapeutics Ltd. - Out-Licensed Products in Pipeline, 2014 11 Chroma Therapeutics Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Chroma Therapeutics Ltd. - Phase II, 2014 13 Chroma Therapeutics Ltd. - Phase I, 2014 14 Chroma Therapeutics Ltd. - Discovery, 2014 15 Chroma Therapeutics Ltd. - Pipeline by Target, 2014 25 Chroma Therapeutics Ltd. - Pipeline by Route of Administration, 2014 26 Chroma Therapeutics Ltd. - Pipeline by Molecule Type, 2014 27 Chroma Therapeutics Ltd. - Pipeline Products by Mechanism of Action, 2014 28 Chroma Therapeutics Ltd. - Recent Pipeline Updates, 2014 29 Chroma Therapeutics Ltd. - Dormant Developmental Projects,2014 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.